SURVYR

SDGR

Schrödinger, Inc.
$26.72
+$2.22 (9.06%)Oct 27 close
Health CareS&P 600 CompareTechnicals
1M3M6M1Y2Y
-51%-25%+1%+27%+52%Oct 2025Oct 2026Apr 202652w high $33.7852w low $10.95
SDGRSPY
Wall St. Highest PT $32.00 (+19.8%) Wall St. Avg PT $25.86 (-3.2%)
$11$17$22$27$33POC $12Hi $32Avg $26
Underwater Drawdown %Max DD -50.1%Current -18.0%
0.0%-50.1%
Relative Strength vs SPY+7.0% vs SPYOutperforming
+63%0%-63%
1W
+$3.32 (14.19%)
1M
−$2.13 (7.38%)
3M
+$11.43 (74.75%)
6M
+$14.48 (118.30%)
YTD
+$8.84 (49.44%)
1Y
+$4.55 (20.52%)

Chart

Loading live chart…

Ratings & dials

1m · 5m · 15m · 1h · 4h · 1D

Analyst & Morningstar ratings

Consensus · Targets · Morningstar
Wall Street analyst consensus
SellHoldStrong Buy
Buy
7 analysts · mean score 1.57
1 = Strong Buy · 5 = Sell
Strong Buy00%
Buy571%
Hold229%
Underperform00%
Sell00%
Wall Street consensus
Analyst price targets
Current price$26.72
Average target$25.86
−$0.86 (−3.2%) downsideaverage target vs current price
CurrentAverageMedian
Low$17.00
Median$30.00
High$32.00
12-month Wall Street target range
Recent analyst rating changes · 30
Reiterated
2026-10-20 · UBS reiterated Neutral on SDGR
Reiterated
2026-10-16 · Keybanc reiterated Overweight on SDGR
Reiterated
2026-10-13 · TD Cowen reiterated Buy on SDGR
Reiterated
2026-10-12 · BMO Capital reiterated Outperform on SDGR
Reiterated
2026-05-14 · Morgan Stanley reiterated Equal-Weight on SDGR
Reiterated
2026-04-08 · Keybanc reiterated Overweight on SDGR
All analyst rating changes ›

Third-party ratings, not SURVYR.'s views.

Key stats & company

Market value$2.0B
P/E (next 12 months, estimated)-19.8
52-week range$10.95 – $33.78
Revenue growth (latest quarter vs a year ago)+7.5%
Dividend yieldNo dividend
Analyst consensusBuy (7)
Average analyst price target$25.86 (-3%)

What they do

Schrödinger, Inc. develops physics-based computational platform that enables discovery of novel molecules for drug development and materials applications in the United States, the Asia-Pacific, Europe, Middle East, Africa, and internationally. The company operates in two segments, Software and Drug Discovery. The Software segment sells its software to transform molecular discovery for life sciences and materials science industries.

Healthcare · Health Information Services
Valuation and fundamentals

Valuation & fundamentals

Loading the valuation from SEC filings…

For information only · Important disclosures

Grades vs sector

Momentum
77th percentile in sector
B+
12-1 return: +47.6%
Percentile within its GICS sector across the S&P 1500.
Growth
45th percentile in sector
C
Revenue growth (YoY): +7.5%
Percentile within its GICS sector across the S&P 1500.
Value
Not enough data yet
–
Forward E/P: – · EBITDA/EV: –
Percentile within its GICS sector across the S&P 1500.
Profitability
9th percentile in sector
D-
Profit margin: -21.0% · Return on equity: -16.2%
Percentile within its GICS sector across the S&P 1500.
Revisions
Not enough data yet
–
EPS estimate change, 30 days (current FY): –
30-day change in analysts' current-year EPS estimate; graded across covered stocks.

Systematic Models

Not held by any of our 7 live models right now.

Quality Growth
Outside this model's universe or screens
 Momentum Top 15
Outside this model's universe or screens
 Momentum Blend
Not in the current book
 New Highs Growth
ranked 76 of 589 · 12-month momentum -2.7%
 SURVYR. Barbell Momentum & T-Bill Shield
Outside this model's universe or screens
 SURVYR. Physical AI Grid & Power
Outside this model's universe or screens
 SURVYR. Long Book
Not in the current book

Earnings & events

SDGR earningsNext report in 8 days
Next report · quarter Sep 2026
Wed Nov 4, 2026After the close
EPS consensus-$0.52
Revenue consensus$47.6M 6 analysts
Last 4 quarters · EPS vs estimate
Aug 5, 2026-$0.42est -$0.67+37.9%Above estimates
May 5, 2026-$0.62est -$0.57−8.9%Below estimates
Feb 25, 2026-$0.18est -$0.09−100.2%Below estimates
Nov 5, 2025-$0.57est -$0.74+23.0%Above estimates

In line = within 1% of the estimate.

Source: Yahoo Finance · report time: Nasdaq earnings calendar · refreshed 2026-10-27 18:23:54 ET
24-1125-0225-0525-0825-1126-0226-0526-08-0.870.00
EstimateActual (beat)Actual (miss)

Quarterly revenue

QuarterRevenueYoY
2026-06-30$58.9M+7.5%
2026-03-31$58.6M–
2025-12-31$87.2M–
2025-09-30$54.3M–
2025-06-30$54.8M–

News & catalysts

More news
Schrödinger Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Business Wire · Oct 26
Schrödinger to Announce Third Quarter 2026 Financial Results on November 4
Business Wire · Oct 21
UBS Adjusts Schrodinger Price Target to $21 From $19, Maintains Neutral Rating
MT Newswires · Oct 20
Schrödinger Research Published in Nature Reveals New Insights into Lithium-Ion Battery Chemistry
Business Wire · Oct 14
Schrödinger (SDGR) Stock Fair Value Edges Higher As Analyst Views Split On AI Growth
Simply Wall St. · Oct 13
Rating changes
Reiterated
2026-10-20 · UBS reiterated Neutral on SDGR
Reiterated
2026-10-16 · Keybanc reiterated Overweight on SDGR
Reiterated
2026-10-13 · TD Cowen reiterated Buy on SDGR
Reiterated
2026-10-12 · BMO Capital reiterated Outperform on SDGR
Reiterated
2026-05-14 · Morgan Stanley reiterated Equal-Weight on SDGR
Reiterated
2026-04-08 · Keybanc reiterated Overweight on SDGR

Third-party analyst actions, not SURVYR.'s views. All rating changes

Insider trades
Akinsanya Karen
See Remarks · 2026-09-17
Sell
$648.0K
Akinsanya Karen
See Remarks · 2026-09-17
Sell
$280.0K

Stats refreshed 2026-10-27 18:23:54 ET from Yahoo Finance (yfinance). "–" means the data isn't available. Refresh now

Morning Brief (8 AM ET) & Market Close (4:30 PM ET), weekdays

Indexes, sectors, biggest movers, rates, top news, SURVYR. model changes and what's ahead. Free, two short emails each weekday.

Editions

Free. Not investment advice. Unsubscribe anytime.

SURVYR

Free to use. No card, no ads, no auto-renew.

Systematic research · Not investment advice · Hypothetical unless marked Live · Data: Yahoo Finance (15-min delayed), SEC EDGAR, House Clerk · Important disclosures · Contact desk@coteau.app

How it worksOur promiseTermsPrivacyData statusSend feedback
Coteau 0.9 · Oct 21, 2026